Monopar Therapeutics Inc. (MNPR)

Monopar Therapeutics (NASDAQ:MNPR) and Regenicin (OTCMKTS:RGIN) Head-To-Head Contrast

Monopar Appoints Jeffrey D. Kent, M.D.

Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy'

Here Are Thursday’s Top Wall Street Analyst Research Calls: Abbott Labs, AbbVie, Akamai Technologies, Five Below, Keurig Dr. Pepper, Salesforce, Stryker, StubHub, and More

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team